|Have Questions?||Leave a Message or Start an on-line Chat|
In order to elicit an immune response, CUSABIO immunized an animal with a human MAP2K1-derived peptide. B cells were isolated from the immunized animal and fused with myeloma cells, resulting in the formation of hybridoma cells. Through careful screening, a specific hybridoma cell clone that produces MAP2K1-specific antibodies was selected. RNA was extracted from the chosen hybridoma cells, and the genes that encode the MAP2K1 antibody's heavy and light chains were amplified using reverse transcription PCR. These amplified genes were then cloned into an expression vector and transfected into a host system to enable antibody expression. The MAP2K1 recombinant monoclonal antibodies were purified from the cell culture supernatant using affinity chromatography. Rigorous validation using ELISA, WB, IHC, and IP assays confirmed the binding specificity and affinity of the recombinant monoclonal MAP2K1 antibody with both human and rat MAP2K1 protein.
There are currently no reviews for this product.